Vaxcyte, Inc.
About Vaxcyte, Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$766.6M
- Total assets
- $3.0B
- Market cap
- $6.8B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $569.5M
- Operating income
- -$569.5M
- Net income
- -$463.9M
- EPS (basic)
- $-3.80
- EPS (diluted)
- $-3.80
Balance sheet
- Total assets
- $3.5B
- Current assets
- $1.8B
- Total liabilities
- $205.5M
- Current liabilities
- $140.2M
- Shareholders’ equity
- $3.3B
Cash flow
- Operating cash flow
- -$452.6M
- Investing cash flow
- -$2.0B
- Financing cash flow
- $2.4B
- Net cash flow
- -$9.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.8B
- EPS (diluted)
- $-3.8
- Shares outstanding
- 147.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 12, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $766.6M.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vaxcyte, Inc..
Write a review
News about Vaxcyte, Inc.
News & sentiment via Polygon.io
